bioRxivPhysiology
Microvasculopathy And Soft Tissue Calcification In Mice Are Governed by Fetuin-A, Pyrophosphate And Magnesium
A. Babler, C. Schmitz, A. Buescher, M. Herrmann, F. Gremse, T. G. Gorgels, J. Floege, W. Jahnen-Dechent
Abstract
ObjectiveCalcifications can disrupt organ function in the cardiovascular system and the kidney, and are particularly common in patients with chronic kidney disease (CKD). Fetuin-A deficient mice maintained against the genetic background DBA/2 exhibit particularly severe soft tissue calcifications, while fetuin-A deficient C57BL/6 mice remain healthy. We employed molecular genetic analysis to identify risk factors of calcification in fetuin-A deficient mice. We sought to identify pharmaceutical therapeutic target that could be influenced by dietary of parenteral supplementation.\n\nApproach and ResultsWe studied the progeny of an intercross of fetuin-A deficient DBA/2 and C57BL/6 mice to identify candidate risk genes involved in calcification. We determined that a hypomorphic mutation of the Abcc6 gene, a liver ATP transporter supplying systemic pyrophosphate, and failure to regulate the TRPM6 magnesium transporter in kidney were associated with severity of calcification. Calcification prone fetuin-A deficient mice were alternatively treated with dietary phosphate restriction, magnesium supplementation, or by parenteral administration of fetuin-A or pyrophosphate. All treatments markedly reduced soft tissue calcification, demonstrated by computed tomography, histology and tissue calcium measurement.\n\nConclusionsWe show that pathological ectopic calcification in fetuin-A deficient DBA/2 mice is caused by a compound deficiency of three major extracellular and systemic inhibitors of calcification, namely fetuin-A, pyrophosphate, and magnesium. All three of these are individually known to contribute to stabilize protein-mineral complexes and thus inhibit mineral precipitation from extracellular fluid. We show for the first time a compound triple deficiency that can be treated by simple dietary or parenteral supplementation. This is of special importance in patients with advanced CKD, who commonly exhibit reduced serum fetuin-A, pyrophosphate and magnesium levels.\n\nSubject CodesAnimal Models of Human Disease, Fibrosis, Inflammation, Proteomics, Peripheral Vascular Disease
- organism: mouse
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Microvasculopathy, Luminal Calcification and Premature Aging in Fetuin-A Deficient Mice
M. Herrmann, A. Babler, … W. Jahnen-Dechent·bioRxiv·Oct 4, 2019
- Loss of PKCα increases arterial medial calcification in a uremic mouse model of chronic kidney disease
S. J. Borland, C. Facchi, … A. E. Canfield·bioRxiv·May 20, 2020
- Cell-based calcification assays - magnesium overrules calcium phosphate saturation in overall outcome
Aaron M. Morgan, Christian Hasberg, … Willi Jahnen‐Dechent·bioRxiv·Dec 25, 2025
- Phosphocitrate Is Superior to Pyrophosphate in Preventing Soft Connective Tissue Calcification in a Mouse Model of Pseudoxanthoma Elasticum
Ibtesam Rajpar, C. Shao, … Koen van de Wetering·bioRxiv·Jul 16, 2026
- Arterial Elastin Abundance, Rather Than Orthologue Origin, Modulates Medial Arterial Calcification in Matrix Gla Protein-Deficient Mice
Juliana Marulanda, Ophélie Gourgas, … Monzur Murshed·bioRxiv·Sep 1, 2026
- The role of Platelet-derived growth factor (PDGF) in uremic vascular calcification.
Burcu Yesilyurt Öztürk, Li Zhang, … Peter Boor·bioRxiv·Jul 9, 2025